IBERE PHARMACEUTICALS
2005 Market Street, Suite 2030
Philadelphia, PA 19103
February 24, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attn: Todd K. Schiffman
Re: Ibere Pharmaceuticals
Registration Statement on Form S-1
File No. 333-252863
Dear Mr. Schiffman:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned Ibere Pharmaceuticals (the “Company”) respectfully requests that the effective date for the above-referenced Registration Statement be accelerated so that such Registration Statement will be declared effective at 4:00 p.m. Eastern Time on Thursday, February 25, 2021, or as soon thereafter as is practicable, or at such other time as the Company or its outside counsel, Shearman & Sterling LLP, request by telephone that such Registration Statement be declared effective.
Please contact our outside counsel, Carmelo M. Gordian of Shearman & Sterling LLP at (512) 647-1902 as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter. Thank you for your attention to this matter.
| Sincerely, | |
| Ibere Pharmaceuticals | |
| /s/ Osagie Imasogie | |
| Osagie Imasogie | |
| Chief Executive Officer |
| cc: | Carmelo M. Gordian, Shearman & Sterling LLP |
| SHEARMAN.COM |
| Shearman & Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners. |
